Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study.
Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Migkou M, Theodorakakou F, Spiliopoulou V, Kostopoulos IV, Syrigou RE, Eleutherakis-Papaiakovou E, Gkolfinopoulos S, Tsitsilonis OE, Kastritis E, Dimopoulos MA.
Terpos E, et al. Among authors: kastritis e.
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284347. Online ahead of print.
Haematologica. 2024.
PMID: 38356458
Free article.